keyword
Keywords N-acetylcysteine and psychiatr...

N-acetylcysteine and psychiatric disorders

https://read.qxmd.com/read/38514990/unconjugated-hyperbilirubinemia-in-acetaminophen-related-acute-liver-failure
#1
JOURNAL ARTICLE
Marie Philippart, Jean-Baptiste Mesland, Vincent Haufroid, Christine Collienne, Philippe Hantson
BACKGROUND In the absence of liver transplantation, the natural history of acetaminophen-induced liver failure is characterized by a progressive increase of liver function tests, including bilirubin mainly as its conjugated form. The presence of high levels of unconjugated bilirubin is more unusual; its etiology is unclear and its prognostic factor has been poorly investigated. CASE REPORT A 52-year-old man with a history of chronic analgesics, alcohol, and illicit drug abuse developed acute liver failure in relationship with the ingestion of largely supra-therapeutic doses of acetaminophen over the days preceding admission...
March 22, 2024: American Journal of Case Reports
https://read.qxmd.com/read/38485889/current-understanding-of-compulsive-sexual-behavior-disorder-and-co-occurring-conditions-what-clinicians-should-know-about-pharmacological-options
#2
REVIEW
Gemma Mestre-Bach, Marc N Potenza
Compulsive sexual behavior disorder (CSBD) has recently been recognized as a psychiatric disorder. Pharmacological treatments for CSBD have received little study and thus have limited empirical support. The main objective of the present work is to review existing literature on the efficacy of different drugs on the symptomatology of CSBD, including the subtype of problematic pornography use (PPU). The main pharmacological approaches to treating CSBD have included opioid antagonists (naltrexone and nalmefene), selective serotonin reuptake inhibitors (paroxetine, citalopram, fluoxetine, and sertraline), mood stabilizers (topiramate), tricyclic antidepressants (clomipramine), serotonin antagonist and reuptake inhibitors (nefazodone), and N-acetylcysteine...
March 14, 2024: CNS Drugs
https://read.qxmd.com/read/38296815/emerging-drugs-for-the-treatment-of-irritability-associated-with-autism-spectrum-disorder
#3
REVIEW
Ahmad Shamabadi, Hanie Karimi, Razman Arabzadeh Bahri, Mohsen Motavaselian, Shahin Akhondzadeh
INTRODUCTION: Autism spectrum disorder (ASD) is an early-onset disorder with a prevalence of 1% among children and reported disability-adjusted life years of 4.31 million. Irritability is a challenging behavior associated with ASD, for which medication development has lagged. More specifically, pharmacotherapy effectiveness may be limited against high adverse effects (considering side effect profiles and patient medication sensitivity); thus, the possible benefits of pharmacological interventions must be balanced against potential adverse events in each patient...
March 2024: Expert Opinion on Emerging Drugs
https://read.qxmd.com/read/37386885/effects-of-n-acetylcysteine-on-oxidative-stress-biomarkers-depression-and-anxiety-symptoms-in-patients-with-multiple-sclerosis
#4
RANDOMIZED CONTROLLED TRIAL
Golsa Khalatbari Mohseni, Seyed Ahmad Hosseini, Nastaran Majdinasab, Bahman Cheraghian
AIM: N-acetylcysteine (NAC), a thiol-containing antioxidant and glutathione (GSH) precursor, attenuates oxidative stress, and possibly improves psychiatric disorders. This study aimed to evaluate the effects of oral NAC on oxidative stress, depression, and anxiety symptoms in patients with multiple sclerosis (MS). METHODS: This clinical trial was conducted on 42 MS patients randomly assigned to intervention (n = 21) and control (n = 21) groups...
September 2023: Neuropsychopharmacology Reports
https://read.qxmd.com/read/37147043/mood-disorders-in-youth-complementary-and-integrative-medicine
#5
REVIEW
Kirti Saxena, Sherin Kurian, Reena Kumar, L Eugene Arnold, Deborah R Simkin
Omega-3 polyunsaturated fatty acids, probiotics, vitamin C, vitamin D, folic acid and L-methyl folate, broad-spectrum micronutrients, N-acetylcysteine, physical activity, herbs, bright light therapy, melatonin, saffron, meditation, school-based interventions, and transcranial photobiomodulation are reviewed, with a focus on their use for treating mood disorders in children and adolescents. For each treatment, all published randomized controlled trials are summarized.
April 2023: Child and Adolescent Psychiatric Clinics of North America
https://read.qxmd.com/read/37132085/who-responds-to-a-multi-component-treatment-for-cannabis-use-disorder-using-multivariable-and-machine-learning-models-to-classify-treatment-responders-and-non-responders
#6
JOURNAL ARTICLE
Rachel L Tomko, Bethany J Wolf, Erin A McClure, Matthew J Carpenter, Kathryn M Magruder, Lindsay M Squeglia, Kevin M Gray
BACKGROUND AND AIMS: Treatments for cannabis use disorder (CUD) have limited efficacy and little is known about who responds to existing treatments. Accurately predicting who will respond to treatment can improve clinical decision-making by allowing clinicians to offer the most appropriate level and type of care. This study aimed to determine whether multivariable/machine learning models can be used to classify CUD treatment responders vs. non-responders. METHODS: This secondary analysis used data from a National Drug Abuse Treatment Clinical Trials Network (NIDA CTN) multi-site outpatien t clinical trial in the United States of America...
May 2, 2023: Addiction
https://read.qxmd.com/read/37119225/the-impact-of-n-acetylcysteine-on-major-depression-qualitative-observation-and-mixed-methods-analysis-of-participant-change-during-a-12-week-randomised-controlled-trial
#7
JOURNAL ARTICLE
Samantha E Russell, David R Skvarc, Mohammadreza Mohebbi, David Camfield, Linda K Byrne, Alyna Turner, Melanie M Ashton, Michael Berk, Seetal Dodd, Gin S Malhi, Sue M Cotton, Ashley I Bush, Olivia M Dean
OBJECTIVE: N -acetylcysteine (NAC) is a novel therapeutic agent with multiple mechanisms of action in the central nervous system and a favourable side effect profile. Clinical evidence indicates that adjunctive NAC may reduce the severity of depressive symptoms in individuals with major depressive disorder (MDD). METHODS: A 12-week randomised controlled trial of 2,000 mg/day adjunctive NAC for MDD found no significant improvement at the primary endpoint (week 12) but did see improvements at the post-discontinuation interview (week 16)...
May 30, 2023: Clinical Psychopharmacology and Neuroscience: the Official Scientific Journal of the Korean College of Neuropsychopharmacology
https://read.qxmd.com/read/37108481/chronic-n-acetyl-cysteine-treatment-enhances-the-expression-of-the-immediate-early-gene-nr4a1-in-response-to-an-acute-challenge-in-male-rats-comparison-with-the-antidepressant-venlafaxine
#8
JOURNAL ARTICLE
Paola Brivio, Maria Teresa Gallo, Piotr Gruca, Magdalena Lason, Ewa Litwa, Fabio Fumagalli, Mariusz Papp, Francesca Calabrese
Despite several antidepressant treatments being available in clinics, they are not effective in all patients. In recent years, N-acetylcysteine (NAC) has been explored as adjunctive therapy for many psychiatric disorders, including depression, for its antioxidant properties. Given the promising efficacy of this compound for the treatment of such pathologies, it is fundamental to investigate, at the preclinical level, the ability of the drug to act in the modulation of neuroplastic mechanisms in basal conditions and during challenging events in order to highlight the potential features of the drug useful for clinical efficacy...
April 15, 2023: International Journal of Molecular Sciences
https://read.qxmd.com/read/36835209/n-acetylcysteine-suppresses-microglial-inflammation-and-induces-mortality-dose-dependently-via-tumor-necrosis-factor-%C3%AE-signaling
#9
JOURNAL ARTICLE
Mai Sakai, Zhiqian Yu, Masayuki Taniguchi, Rosanne Picotin, Nanami Oyama, David Stellwagen, Chiaki Ono, Yoshie Kikuchi, Ko Matsui, Miharu Nakanishi, Hatsumi Yoshii, Tomoyuki Furuyashiki, Takaaki Abe, Hiroaki Tomita
N-acetylcysteine (NAC) is an antioxidant that prevents tumor necrosis factor (TNF)-α-induced cell death, but it also acts as a pro-oxidant, promoting reactive oxygen species independent apoptosis. Although there is plausible preclinical evidence for the use of NAC in the treatment of psychiatric disorders, deleterious side effects are still of concern. Microglia, key innate immune cells in the brain, play an important role in inflammation in psychiatric disorders. This study aimed to investigate the beneficial and deleterious effects of NAC on microglia and stress-induced behavior abnormalities in mice, and its association with microglial TNF-α and nitric oxide (NO) production...
February 14, 2023: International Journal of Molecular Sciences
https://read.qxmd.com/read/36829952/potential-of-nano-antioxidants-and-nanomedicine-for-recovery-from-neurological-disorders-linked-to-long-covid-syndrome
#10
REVIEW
Thelma Akanchise, Angelina Angelova
Long-term neurological complications, persisting in patients who cannot fully recover several months after severe SARS-CoV-2 coronavirus infection, are referred to as neurological sequelae of the long COVID syndrome. Among the numerous clinical post-acute COVID-19 symptoms, neurological and psychiatric manifestations comprise prolonged fatigue, "brain fog", memory deficits, headache, ageusia, anosmia, myalgias, cognitive impairments, anxiety, and depression lasting several months. Considering that neurons are highly vulnerable to inflammatory and oxidative stress damages following the overproduction of reactive oxygen species (ROS), neuroinflammation and oxidative stress have been suggested to dominate the pathophysiological mechanisms of the long COVID syndrome...
February 6, 2023: Antioxidants (Basel, Switzerland)
https://read.qxmd.com/read/36795166/beneficial-in-vitro-effect-of-n-acetylcysteine-and-coenzyme-q10-on-dna-damage-in-neurodegenerative-niemann-pick-type-c-1-disease-preliminary-results
#11
JOURNAL ARTICLE
Tatiane G Hammerschmidt, Gilian B Guerreiro, Bruna Donida, Marco Raabe, Rejane G Kessler, Matheus B Ferro, Dinara J Moura, Roberto Giugliani, Carmen R Vargas
Niemann-Pick type C1 (NP-C1) is a lysosomal storage disease (LSD) caused by mutations in NPC1 gene that lead to defective synthesis of the respective lysosomal transporter protein and cholesterol accumulation in late endosomes/lysosomes (LE/L) compartments, as well as glycosphingolipids GM2 and GM3 in the central nervous system (CNS). Clinical presentation varies according to the age of onset and includes visceral and neurological symptoms, such as hepatosplenomegaly and psychiatric disorders. Studies have been associating the pathophysiology of NP-C1 with oxidative damage to lipids and proteins, as well as evaluating the benefits of adjuvant therapy with antioxidants for this disease...
July 2023: Naunyn-Schmiedeberg's Archives of Pharmacology
https://read.qxmd.com/read/36634809/thiol-disulfide-homeostasis-in-psychiatric-disorders-a-comprehensive-review
#12
REVIEW
Merve Ergin Tuncay, Murat Ilhan Atagun, Ozcan Erel
Thiol-disulfide couple maintains an intracellular redox status. Dynamic thiol-disulfide homeostasis acts crucial parts in metabolic processes involving signal mechanisms, inflammation, antioxidant defense. Thiol-disulfide homeostasis have been implicated in numerous diseases. In this comprehensive review we identified the studies that examined the thiol-disulfide homeostasis in psychiatric disorders. Most cases demonstrated alterations in thiol-disulfide homeostasis and in most of them the thiol-disulfide balance tended to change direction to the disulfide side, that is, to the oxidative side...
April 20, 2023: Progress in Neuro-psychopharmacology & Biological Psychiatry
https://read.qxmd.com/read/36225391/chronic-n-acetylcysteine-treatment-improves-anhedonia-and-cognition-in-a-mouse-model-of-the-schizophrenia-prodrome
#13
JOURNAL ARTICLE
Lukas Marius Bühner, Sampath K T Kapanaiah, Dennis Kätzel
Schizophrenia is a severe psychiatric disorder whose neurodevelopmental pathogenesis includes a prodromal phase before its diagnostically decisive-namely psychotic-symptoms are present. This prodrome is characterized by cognitive and affective deficits, and it may constitute a critical time period for an early therapeutic intervention to improve or even prevent further disease development. N-acetylcysteine (NAC) is an easily repurposable compound that has recently shown promise in improving non-psychotic symptoms in patients with established schizophrenia...
2022: Frontiers in Behavioral Neuroscience
https://read.qxmd.com/read/35952519/n-acetylcysteine-in-the-treatment-of-compulsive-sexual-behavior-disorder-a-case-series
#14
JOURNAL ARTICLE
Austin W Blum, Jon E Grant
Although compulsive sexual behavior disorder (CSBD) is a relatively common disorder with an estimated prevalence of at least 3%, clinicians currently have limited evidence and no FDA-approved drugs to guide their treatment of this condition. N-acetylcysteine (NAC), an amino acid that seems to restore extracellular levels of glutamate in the nucleus accumbens, has previously demonstrated efficacy in treating multiple psychiatric disorders, including substance use disorders and putative behavioral addictions...
October 2022: Journal of Psychiatric Research
https://read.qxmd.com/read/34509090/repurposed-drugs-as-adjunctive-treatments-for-mania-and-bipolar-depression-a-meta-review-and-critical-appraisal-of-meta-analyses-of-randomized-placebo-controlled-trials
#15
JOURNAL ARTICLE
Francesco Bartoli, Daniele Cavaleri, Bianca Bachi, Federico Moretti, Ilaria Riboldi, Cristina Crocamo, Giuseppe Carrà
Several drugs previously tested in clinical trials and approved for different indications have been repurposed for bipolar disorder. We carried out a systematic meta-review of meta-analyses of randomized placebo-controlled trials investigating repurposed drugs as adjunctive treatments for mania and bipolar depression. We performed a critical appraisal using 'A MeaSurement Tool to Assess systematic Reviews' Version 2 (AMSTAR 2). We synthesized results on efficacy, tolerability, and safety, assessing evidence quality according to the 'Grading of Recommendations, Assessment, Development and Evaluations' (GRADE) approach...
November 2021: Journal of Psychiatric Research
https://read.qxmd.com/read/34438354/baseline-serum-amino-acid-levels-predict-treatment-response-to-augmentation-with-n-acetylcysteine-nac-in-a-bipolar-disorder-randomised-trial
#16
RANDOMIZED CONTROLLED TRIAL
Chiara C Bortolasci, Alyna Turner, Mohammadreza Mohebbi, Zoe Sj Liu, Melanie Ashton, Laura Gray, Wolfgang Marx, Adam J Walker, Greg M Kowalski, Felice Jacka, Michael Berk, Olivia M Dean, Ken Walder
N-acetylcysteine (NAC) acts on glutamatergic and redox systems, two systems implicated in the pathophysiology of bipolar disorder (BD). This has led to the investigation of NAC as a potential candidate for the treatment of BD. The aim of this study was to investigate metabolomic markers to identify predictors of NAC response in a cohort of BD participants. This study is a secondary analysis of a 16-week, multi-site, randomized, double-blinded, parallel-group, placebo-controlled trial in BD participants with a current acute depressive episode...
October 2021: Journal of Psychiatric Research
https://read.qxmd.com/read/34334731/lifestyle-interventions-in-the-treatment-of-obsessive-compulsive-and-related-disorders-a-systematic-review
#17
JOURNAL ARTICLE
Mary-Ellen E Brierley, Emma M Thompson, Lucy Albertella, Leonardo F Fontenelle
OBJECTIVE: Lifestyle medicine is increasingly important in psychiatry for its efficacy as a transdiagnostic treatment, its preventative potential, and its increased tolerability compared with first-line strategies. Although the impact of lifestyle medicine is strong across many psychiatric illnesses, our understanding of the effectiveness of lifestyle interventions in treating obsessive-compulsive and related disorders (OCRDs) is minimal. We aimed to conduct a systematic review examining the effect of lifestyle interventions (targeting diet, exercise, sleep, stress management, and tobacco/alcohol use) on OCRD symptoms...
October 1, 2021: Psychosomatic Medicine
https://read.qxmd.com/read/34308314/n-acetylcysteine-nac-for-methamphetamine-dependence-a-randomised-controlled-trial
#18
JOURNAL ARTICLE
Rebecca McKetin, Olivia M Dean, Alyna Turner, Peter J Kelly, Brendan Quinn, Dan I Lubman, Paul Dietze, Gregory Carter, Peter Higgs, Barbara Sinclair, David Reid, Amanda L Baker, Victoria Manning, Nina Te Pas, Tamsin Thomas, Ramez Bathish, Dayle K Raftery, Anna Wrobel, Lucy Saunders, Shalini Arunogiri, Frank Cordaro, Harry Hill, Scott Hall, Philip J Clare, Mohammadreza Mohebbi, Michael Berk
BACKGROUND: Methamphetamine dependence is a significant global health concern for which there are no approved medications. The cysteine prodrug, N-acetylcysteine (NAC), has been found to ameliorate glutamate dysregulation in addiction, and to reduce craving for methamphetamine and other drugs. We evaluated the efficacy and safety of NAC as a pharmacotherapy for methamphetamine dependence. METHODS: A parallel double-blind randomised placebo-controlled trial of people dependent on methamphetamine recruited from Geelong, Melbourne and Wollongong, Australia, between July 2018 and December 2019...
August 2021: EClinicalMedicine
https://read.qxmd.com/read/34264451/therapeutic-approaches-employing-natural-compounds-and-derivatives-for-treating-bipolar-disorder-emphasis-on-experimental-models-of-the-manic-phase
#19
REVIEW
Vânia Machado Recart, Luiza Spohr, Mayara Sandrielly Pereira Soares, Karina Pereira Luduvico, Francieli Moro Stefanello, Roselia Maria Spanevello
Bipolar disorder (BD) is a complex psychiatric disease characterized by mood swings that include episodes of mania and depression. Given its cyclical nature, BD is especially hard to model; however, the standard practice has been to mimic manic episodes in animal models. Despite scientific advances, the pathophysiology of BD is not fully understood, and treatment remains limited. In the last years, natural products have emerged as potential neuroprotective agents for the treatment of psychiatric diseases. Thus, the aim of this review was to explore the therapeutic potential of natural compounds and derivatives against BD, taking into account preclinical and clinical studies...
October 2021: Metabolic Brain Disease
https://read.qxmd.com/read/34072255/do-autophagy-enhancers-ros-scavengers-alleviate-consequences-of-mild-mitochondrial-dysfunction-induced-in-neuronal-derived-cells
#20
JOURNAL ARTICLE
Damri Odeya, Natour Sarya, Agam Galila
Mitochondrial function is at the nexus of pathways regulating synaptic-plasticity and cellular resilience. The involvement of brain mitochondrial dysfunction along with increased reactive oxygen species (ROS) levels, accumulating mtDNA mutations, and attenuated autophagy is implicated in psychiatric and neurodegenerative diseases. We have previously modeled mild mitochondrial dysfunction assumed to occur in bipolar disorder (BPD) using exposure of human neuronal cells (SH-SY5Y) to rotenone (an inhibitor of mitochondrial-respiration complex-I) for 72 and 96 h, which exhibited up- and down-regulation of mitochondrial respiration, respectively...
May 27, 2021: International Journal of Molecular Sciences
keyword
keyword
78779
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.